Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
about
Energy disruptors: rising stars in anticancer therapy?Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.Uveal melanoma cell growth is inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase.AICAR induces mitochondrial apoptosis in human osteosarcoma cells through an AMPK-dependent pathway.Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphomaTargeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax.Chemo-Genetic Interactions Between Histone Modification and the Antiproliferation Drug AICAR Are Conserved in Yeast and Humans.AICAR Antiproliferative Properties Involve the AMPK-Independent Activation of the Tumor Suppressors LATS 1 and 2.A combined tissue engineered / in silico signature tool for patient stratification in lung cancer.Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models
P2860
Q26771300-4D65C9D5-313F-4B9D-8892-161B2B5E58A6Q30395557-CC671BF2-A1B2-4F3F-BB1D-210EA708803DQ33872396-DE549BE8-2A12-4E9D-A581-DBA7A5C59E63Q37530765-41D29FFB-26F6-4DA4-8FBE-773E4B0EAD7CQ37718466-C98EA10C-5295-49C9-B533-A3330D5F3859Q38606849-CE98154D-29D6-4BA6-86C2-F1752545EE5BQ44633375-333D6D47-4FBB-4D35-A59B-22D3FE90DA7EQ46177112-B4B02141-2062-49E9-A907-67340619F4A2Q54112169-89DAD191-9F0F-4F6E-A251-7E74CA2194C9Q54978277-C1E1877B-3050-4023-97A9-854F8B5816E4Q58603752-74510C79-D86E-42E7-B149-EE5C5A5F7632
P2860
Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Acadesine for patients with re ...... a multicenter phase I/II study
@ast
Acadesine for patients with re ...... a multicenter phase I/II study
@en
type
label
Acadesine for patients with re ...... a multicenter phase I/II study
@ast
Acadesine for patients with re ...... a multicenter phase I/II study
@en
prefLabel
Acadesine for patients with re ...... a multicenter phase I/II study
@ast
Acadesine for patients with re ...... a multicenter phase I/II study
@en
P2093
P2860
P50
P921
P1476
Acadesine for patients with re ...... a multicenter phase I/II study
@en
P2093
Andrew Saunders
Ann Janssens
Bruno Cazin
Clara Campàs
Eric Van Den Neste
Mercè de Frias
P2860
P2888
P304
P356
10.1007/S00280-012-2033-5
P577
2012-12-11T00:00:00Z
P5875
P6179
1028827252